View Older Stories View More Recent Stories

Aug 11, 2021 06:30PM FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
Aug 11, 2021 07:05AM IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
Aug 10, 2021 06:45AM FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
Aug 10, 2021 06:43AM Merck's (MRK) KEYTRUDA® (pembrolizumab) Granted FDA Priority Review as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Aug 10, 2021 06:42AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surg
Aug 5, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KE
Jul 29, 2021 12:30PM Merck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
Jul 29, 2021 06:30AM Merck Announces Second-Quarter 2021 Financial Results
Jul 27, 2021 01:34PM Merck Announces Fourth-Quarter 2021 Dividend
Jul 27, 2021 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1
Jul 27, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
Jul 27, 2021 06:33AM Merck (MRK) Announces FDA Approves KEYTRUDA for Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment
Jul 27, 2021 06:30AM FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as
Jul 22, 2021 06:46AM Merck (MRK) Announces FDA Approves KEYTRUDA Plus LENVIMA Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 22, 2021 06:45AM FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Jul 21, 2021 07:14AM Merck (MRK) Announces VERQUVO Approved in the European Union
Jul 21, 2021 07:14AM VERQUVO® (vericiguat) Approved in the European Union
Jul 20, 2021 06:11AM Merck (MRK) Presents New Data from Ongoing Phase 2a Trial Evaluating Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS
Jul 20, 2021 06:00AM Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
Jul 19, 2021 08:12AM Ligand's (LGND) Partner Merck (MRK) Receives FDA Approval for VAXNEUVANCE for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Jul 19, 2021 07:23AM Merck (MRK) Announces FDA Approval of VAXNEUVANCE to Prevent Invasive Pneumococcal Disease
Jul 16, 2021 05:15PM Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
Jul 15, 2021 01:30PM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemother
Jul 12, 2021 07:00AM Merck (MRK) to Present New Data from Broad HIV Program at IAS 2021
Jul 12, 2021 06:55AM Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021
Jul 12, 2021 06:46AM Merck (MRK) Announces Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at ECCMID
Jul 12, 2021 06:45AM Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & I
Jul 6, 2021 06:47AM FDA Announces Expanded Indication for Merck's (MRK) KEYTRUDA® in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Jul 6, 2021 06:45AM FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Jul 1, 2021 04:06PM Merck (MRK) Provides Update on KEYTRUDA Indication in Third-Line Gastric Cancer in the US
Jul 1, 2021 04:05PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
Jun 30, 2021 04:00PM Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
Jun 29, 2021 09:05AM Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy
Jun 29, 2021 06:46AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma
Jun 29, 2021 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Jun 24, 2021 11:00AM Merck (MRK) Appoints Michael Klobuchar Chief Strategy Officer
Jun 24, 2021 11:00AM Merck Appoints Michael Klobuchar Chief Strategy Officer
Jun 24, 2021 06:47AM Merck's (MRK) LYNPARZA Approved in China for Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Jun 24, 2021 06:45AM LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Jun 22, 2021 06:47AM Merck (MRK) Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS and PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Jun 22, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Jun 17, 2021 10:38AM MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 17, 2021 06:45AM Merck to Participate in the Guggenheim Biopharma Strategy Series
Jun 16, 2021 08:00AM Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
Jun 15, 2021 07:00AM AtriCure Names Two New Members to the Board of Directors
Jun 9, 2021 06:46AM Merck (MRK) Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 9, 2021 06:45AM Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 7, 2021 04:30PM Merck's (MRK) MSD Animal Health to Acquire Assets of LIC Automation Ltd.
Jun 7, 2021 04:30PM MSD Animal Health to Acquire Assets of LIC Automation Ltd.
Jun 7, 2021 06:48AM Merck (MRK) Reports New Data on KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Versus Sunitinib from Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial
View More Recent Stories View Older Stories